

SUVEN Life Sciences

 Partnering Drug Discovery & Development

.....and beyond!



Vision


To Emerge as a leading player by providing full spectrum services in drug discovery, development, manufacturing and support services under collaboration with leading global life science players



Graduated from Contract Research to Collaborative Research



Suven's Business Model



Collaborative Research Partner (CRP) ... Seamless transition



BUSINESS STRUCUTRE

- In operation since 1989 to 2004 as SUVEN PHARMACEUTICAL LTD.
- Profitable for the last decade
- Transformed to SUVEN LIFE SCIENCES LTD from 2003
- Strong asset base and financial fundamentals
- Pioneering efforts in C-R-A-M-S since 1994
- Pioneering initiatives in DDDSS in 2005
- Relationships with many Global Life Science majors
- IPO in 1995 Listed on NSE and BSE
- More than 300 scientific professional

High growth potential



20 years of Pharmaceutical Relationship

- Profitable every year since founding in 1989
- Listed on NSE & BSE

DDDSS •Leader in CNS based internal discovery in India •State of the art facility, models •Multiple big pharma relationships

CRAMS •Leader and innovator for many NCE based intermediates •600+ projects •380+ R&D professionals

Relationship with more than 22 global pharmaceutical companies

FORMULATIONS •Pharmaceutical product development •Product scale up and manufacturing services

Pharmaceutical Analytical servicesRegulatory management services111



STRATEGIC BUSINESS SEGMENTS

- API's & Intermediates Manufacturing
- Contract Research and Manufacturing
- Services (C-R-A-M-S)
- Formulation Development Centre (FDC)
- Drug Discovery and Development
- Support Services (DDDSS)
- Collaborative Research Partnerships (CRP)

Full spectrum services in Drug Discovery, Development and Manufacturing

Multi facility, Multi location



Corporate Office Biopharma GLP



Suven USA Business office




Jeedimetla Suven R&D-Pilot Plant





Suryapet Suven Intermediate Mfg. facility


Pashamylaram Suven API & Formulation facility SUVEN Life Sciences



Any stage scalable at short time




Reactor Capacities (M³) across Suven's facilities





Reactor Capacities (M³) by MOC





786

HUMAN RESOURCES

Total Employees

– R&D	382
 Manufacturing & Services 	358
 Administration / Sales 	46



HUMAN RESOURCES

	<u>R&D</u>	-	382
_	Analytical Development	-	43
_	Discovery	-	169
_	Process R&D	-	105
_	Formulation Development	-	65



HUMAN RESOURCES

Qualifications:

PhD's / MD	-	31
MS / M Phil / M Tech	-	410
BS / B Tech / Engg. Diploma	-	345

Total - 786



Regulatory Information

(DMF/Product Dossier/Technical Information Submitted)

Regulatory Authority &	AF	Pls	Intermediates		-	g Product/ mulation	
Country	Suven	Customer Specific	Suven	Customer Specific	Suven	Customer Specific	
FDA, USA.	12	4	2	0	1	0	
EDQM	2	0	0	0	0	0	
MHRA, UK	1	0	0	0	0	0	
Netherlands	1	0	0	0	0	0	
17 EU Countries	1	0	0	0	0	0	
Registration at China	2	0	0	0	0	0	
Registration at Korea	2	0	0	0	0	0	
PMDA, Japan	2	0	2	0	0	0	



MANAGEMENT SYSTEMS

- **cGMP (current Good Manufacturing Practices)**
- ISO 9001:2008 (Quality Management System)
- ISO 14001:2004 (Environmental Management System)
- OHSAS 18001:2007 (Occupational Health and Safety Assessment Series)



R&D PROFESSIONAL

- Highly qualified and experienced scientific professional manpower.
- State of the art DST approved R&D facility
- Willing to accept challenging product development opportunities
- Fast technology transfer from laboratory to industrial scale
- New product / process development in collaboration with leading global pharmaceutical / fine chemical companies



RESEARCH & DEVELOPMENT ACTIVITIES

- Synthetic organic Chemistry
- Building Blocks, Scaffolds and Intermediate compounds for generating analogues
- Custom Synthesis of lead compounds in grams and kilograms
- Intermediates in Multi-kilograms
- R & D for process optimization
- R & D for hazardous chemical Reaction
- Collaborative research
- R & D for clean technologies



PRECLINICAL AND CLINICAL DEVELOPMENT SUPPORT

- Contract Research Laboratory
- Custom Synthesis laboratory
- Process Research- optimization of process
- Custom manufacturing- Pilot plant
- Scale-up of synthesis to provide quantities from grams to kilograms
- Synthesis of reference compounds, fully characterized to meet GLP requirement



SCALE-UP/COMMERCIAL SUPPORT

- Scale-up of established processes
- Process optimisation
- Identification of alternate viable synthetic methods
- Scale up synthesis of gram/ kilogram quantities of building blocks
- Manufacture of intermediates



MEDICINAL CHEMISTRY CAPABILITIES

- Support for:
- Lead optimization
- Synthesis of reference compounds
- Starting materials
- Intermediates / Building blocks
- Preparation of compound
- Iibraries





PROJECT MANAGEMENT

♦ A Project Team is led by a Project Manager and a team of scientists to guarantees the quality and the timelines of each project.

The Project Manager is the single point of contact with the Client. The entire communication process is through Secured E-mails, regular teleconferences, videoconferences and periodic Report.

The Project manager will report the progress on a weekly basis, detailing the progress and future direction of the project.

✤Finally a detailed project report will be provided upon the completion of the Project and all the materials and information deemed necessary will be transferred to the client based on the initial terms and conditions of the agreement.



SECURITY / CONFIDENTIALITY

Intellectual Property

Suven Life sciences Limited will strictly adhere and implement the recently approved international patent law.

*To ensure the security and confidentiality of client data, we uses data only for the purpose intended. Access to client data is restricted to the Team leaders working on the respective project and observe strict standards of confidentiality.

*All Confidential Information and any other information in whatever form or medium supplied by the Client to us shall be delivered immediately upon demand at any time until the partnership remains in force or thereafter.

 All confidential information shall remain the property of the Client.



REACTION CAPABILITIES

- Alkylations Acylation Amidation Chiral alkylation Condensation **Cyanation** Cyclo-condensation *****Formylations Grignard reactions Halogenation Using bromine, *chlorine, POCI3 etc., Heck Arylation
- chiral Amines syntheis
 Asymmetric synthesis
 Carbohydrates
 Grignard reaction
 Horner-Emmons Wadsworth
 reaction
 Organoborane



- Hydrogenation using pd/c, Pt/c, Rh/c and Rani-Ni
- Metallation MeLi / n-BuLi / LDA/HMDS
- Mitsunobu Reaction
- **Oxidation Jones, swern, KMnO₄, NalO₄, Nitric acid**
- Reductions Catalytic, Metal hydrides, High pressure, Metal catalysed, Birch reductions, Diborane, LAH, DIBAL-H, Catalytic, NaCNBH₃
- Suzuki Coupling
- Asymmetric synthesis
- Enzymatic resolution



25

For Target molecule without chemistry information

Chemistry route selection phase (1-2 weeks

based on

- Retro-synthetic analysis
- Literature search
- Raw material availability
- Capabilities of chemistry and facilities
- Raw material cost
- Paper costing
- Proof of concept phase
- pilot experiments (2-4 weeks)
- Molecule identification and characterization

Optimization phase (2–3 weeks)

- Process optimization
- process variation
- critical parameters
- In-process control parameters
- specification settings
- safety evaluation.
- Scale-up phase (4-6 weeks)
- Raw material procurement
- Facility identification
- Batch record writing
- Scale-up implementation
- Dispatch of products
- Campaign report writing

Note: This timeline is considering 4-6 steps synthetic process.<u>The timeline</u> may vary if the special raw material is required with respect to scale-up.



For Target molecule with small scale process given

- Raw material availability (one week)
- Capabilities of chemistry and facilities
- Raw material cost
- Paper costing
- Optimization phase (2-4 weeks)
- Process optimization
- process variation
- critical parameters
- In-process control parameters
- specification settings
- safety evaluation.

Scale-up phase (4-6 weeks)

- Raw material procurement
- Facility identification
- Batch record writing
- Scale-up implementation
- Dispatch of products
- Campaign report writing

Note: This timeline is considering 4-6 steps synthetic process. The timeline may vary if the special raw material is required.



CHIRAL TECNOLOGY PRODUCTS

SUFINAMIDE CHIRAL TECHNOLOGY VIZ.,	t-Butylsufinamide (R &S) p-Toluenesulfinamide (R&S) P-Toluenemethane sulfoxide (R&S) 2.4.6-trimethylphenylsulfinamide (R&S)	
PYRROLIDINE RELATED TECHNOLOGY	 3-Hydroxytetrahydrofuran (R&S) 3-hydroxypyrrolidine (R&S) 3-Aminopyrrolidine (R&S) 3-Cyanopyrrolidine (R&S) 3-Carboxypyrrolidine (R&S) 3-Hydroxy-N-benzylpyrroline (R&D) 3-Aminotetrahydrofuran (R&S) Pyrrolidine-3-carboxylic acid (R&S) 	
SUGAR DERVATIVES	4-Hydroxy-2-pyrrolidone (R&S) 2-Hydroxy-1,4-diol (R&S)	27



PROJECT REPORTING

- Gantt Chart provided at start of project
- Weekly reports provided every week of specified days on status
- Teleconferences on periodic basis as per the customer.
- Project coordinator accessible round the clock
- Detailed report submitted within 3-5 weeks on completion of project covering
- Project summary
- Experimental details
- Synthetic Scheme, Raw Materials, Critical Issues, Stepwise Process
- Description, Modifications carried out to documented processes,
- Development history of process on parameters and conditions.
- process safety information.
- Suggestion for further improvement if any
- Literature References,
- Analytical methods and data



ENVIRONMENT AND HEALTH AND SAFETY

Safety

- PPE is a culture
- Apron
- safety glasses
- Safety gloves
- Face shield
- Dust respirator
- Splash Goggle
- Vapor Respirator
- Safety Manager
- Safety Audits
- HAZOP studies

Health

- Pre-employment medical clearance
- Periodic Health Check

Environment

- ***** Waste segregation
- Waste minimization
- Compliance to local laws



Coming together is a beginning Keeping together is progress Working together is success.

-HENRY FORD



THANK YOU